| P50 | author | Bruce A. Mueller | Q37370971 |
| | Gregory Eschenauer | Q56867069 |
| P2093 | author name string | Simon W Lam | |
| P2860 | cites work | New developments in aminoglycoside therapy and ototoxicity | Q24599985 |
| | Aspirin to prevent gentamicin-induced hearing loss | Q28196808 |
| | Different aminoglycoside-resistant phenotypes in a rabbit Staphylococcus aureus endocarditis infection model | Q34106959 |
| | Using population pharmacokinetics to determine gentamicin dosing during extended daily diafiltration in critically ill patients with acute kidney injury | Q34108507 |
| | Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children | Q34157657 |
| | Aminoglycoside adaptive resistance: importance for effective dosage regimens | Q34277787 |
| | Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Y | Q34426508 |
| | Synergism of vancomycin-gentamicin and vancomycin-streptomycin against enterococci | Q35651761 |
| | Influence of hemodialysis on gentamicin pharmacokinetics, removal during hemodialysis, and recommended dosing | Q36666776 |
| | Dialysis in intensive care unit patients with acute kidney injury: continuous therapy is superior | Q36910616 |
| | Back to the future: using aminoglycosides again and how to dose them optimally | Q36916092 |
| | Determinants and impact of multidrug antibiotic resistance in pathogens causing ventilator-associated-pneumonia | Q37105990 |
| | Drug dosing during continuous renal replacement therapy | Q37475122 |
| | Drug therapy in patients undergoing continuous ambulatory peritoneal dialysis. Clinical pharmacokinetic considerations | Q37909313 |
| | Pharmacological considerations for the proper clinical use of aminoglycosides | Q37956403 |
| | Aminoglycosides in septic shock: an overview, with specific consideration given to their nephrotoxic risk | Q38090988 |
| | Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance | Q39828366 |
| | Kill kinetics and regrowth patterns of Escherichia coli exposed to gentamicin concentration-time profiles simulating in vivo bolus and infusion dosing | Q39865745 |
| | Studies on antibiotic syngerism against enterococci. II. Effect of various antibiotics on the uptake of 14 C-labeled streptomycin by enterococci | Q40325773 |
| | Gram-negative bacteraemia in haemodialysis | Q40956405 |
| | Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. | Q41696128 |
| | Comparative pharmacodynamics of gentamicin against Staphylococcus aureus and Pseudomonas aeruginosa | Q42549535 |
| | Gentamicin in hemodialyzed critical care patients: early dialysis after administration of a high dose should be considered | Q42952777 |
| | In vitro pharmacodynamic analysis of single daily dosing versus conventional dosing of gentamicin administered with penicillin against Enterococcus faecalis | Q43747971 |
| | Aminoglycosides in hemodialysis patients: is the current practice of post dialysis dosing appropriate? | Q43872720 |
| | Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration | Q44483617 |
| | Clinical experience with aminoglycosides in dialysis-dependent patients: risk factors for mortality and reassessment of current dosing practices | Q45734205 |
| | Aminoglycosides in intermittent hemodialysis: pharmacokinetics with individual dosing. | Q45936222 |
| | Single, large, daily dosing versus intermittent dosing of tobramycin for treating experimental pseudomonas pneumonia | Q46611376 |
| | N-acetylcysteine use for amelioration of aminoglycoside-induced ototoxicity in dialysis patients | Q47608948 |
| | Gentamicin-induced ototoxicity in hemodialysis patients is ameliorated by N-acetylcysteine | Q50457858 |
| | Dosing of gentamicin in patients with end-stage renal disease receiving hemodialysis. | Q51930719 |
| | Characterization of gentamicin pharmacokinetics in patients hemodialyzed with high-flux polysulfone membranes. | Q53730047 |
| | Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections | Q54297609 |
| P433 | issue | 3 | |
| P921 | main subject | hemodialysis patient | Q126109077 |
| P304 | page(s) | 204-213 | |
| P577 | publication date | 2016-01-12 | |
| P1433 | published in | Seminars in Dialysis | Q15761546 |
| P1476 | title | Dose Timing of Aminoglycosides in Hemodialysis Patients: A Pharmacology View | |
| P478 | volume | 29 | |